Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Investing.com -- Mind Medicine (NASDAQ:MNMD) stock gained 4.7% on Wednesday following news from Marijuana Moment that bipartisan congressional lawmakers met with the Department of Veterans Affairs (VA) Secretary to discuss expanding access to psychedelic medicine for veterans.
Representatives Lou Correa (D-CA) and Jack Bergman (R-MI), founding co-chairs of the Congressional Psychedelic Advancing Therapies (PATH) Caucus, held what they described as a productive meeting with VA Secretary Doug Collins about advancing psychedelic therapies for veterans suffering from conditions like post-traumatic stress disorder (PTSD).
The meeting, which had been requested in May, signals growing government interest in alternative treatments for veterans’ mental health issues. Rep. Correa highlighted the importance of providing veterans with access to psychedelic-assisted therapies, stating, "Too many of these heroes return home with invisible wounds."
Secretary Collins has emerged as a notable advocate for exploring the therapeutic potential of substances such as ibogaine and MDMA. He has been coordinating with other officials including Health and Human Services Secretary Robert F. Kennedy Jr., who recently expressed his intention to expand access to plant-based medicine options within the next 12 months.
Mind Medicine, also known as MindMed, is a clinical-stage biopharmaceutical company that develops psychedelic-inspired medicines and therapies targeting mental health disorders and addiction. The company’s research focuses on creating treatments derived from psychedelics and related compounds for conditions including anxiety, depression, and other brain health disorders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.